Compare Amphastar Pharmaceuticals Inc (AMPH) vs Uber Technologies Inc (UBER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Uber Technologies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Uber Technologies Inc trades at $74.85 (market cap $151.73B). The key difference: Uber Technologies Inc is far larger — about 183.7× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | UBER | |
|---|---|---|
Market Cap | $826.08M | $151.73B |
Sector | Health | Industrials |
52-Week High | $30.81 | $100.10 |
52-Week Low | $16.87 | $68.61 |
Enterprise Value | $1.22B | $158.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Uber trades at $74.54, up 0.26% today, with a bullish technical signal from moving averages and strong analyst consensus. Revenue grew to $52.02 billion in 2025, with net income of $10.05 billion, though margins are expected to moderate. Recent news highlights expansion into robotaxis in Europe and cost-cutting measures, including HR layoffs and AI spending caps.
The outlook remains positive with an 81.67% buy rating from analysts and a $109.25 price target, but risks include competitive pressures in key markets like India, regulatory scrutiny, and projected negative net cash flow in 2026. Earnings volatility, as seen in Q4 2025's miss, adds uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
